Fixed cost deal gives CRO cut of sales if Ph III ends early
CRO Health Decisions has inked a fixed cost outsourcing deal that uses profit sharing as an incentive to finish the trial early.
Archives for May 3, 2011
Parexel laying off 300 & cutting 25-30% of Phase I capacity
Parexel is cutting up to 30 per cent of Phase I capacity and around 300 staff in response to changes in early phase demand.
Prosonix and Sterling complete API commercialisation
Prosonix and Italian partner Sterling have completed the commercialisation of a respiratory active pharmaceutical ingredient (API) using the UK firm’s unique particle engineering technology.
CRL profits up in Q1 on tax benefits but sales drop on falling demand
Tax benefit from the sale of its US Phase I business helped CRO Charles Rivers Laboratories (CRL) to grow profits in the first quarter despite falling revenues and low demand.
Appointments at Savient, Avantor Performance Materials and CorePharma – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Savient, Avantor Performance Materials and CorePharma.
ETP invests in ICVrx’s drug delivery technology for treating epilepsy
Non-profit epilepsy research sponsor, Epilepsy Therapy Project (ETP), has announced it is to invest in central nervous system (CNS) drug delivery specialist, ICVrx, to support the development of novel drug tech designed to tackle refractory epilepsy.